ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1569

Increased Circulating CD14brightCD16+ Intermediate Monocytes Are Regulated By Interleukin-10 in Patients with Rheumatoid Arthritis

Masako Tsukamoto1, Noriyuki Seta2, Keiko Yoshimoto1, Katsuya Suzuki1, Kunihiro Yamaoka1 and Tsutomu Takeuchi1, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Department of Internal Medicine, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Fc receptors, interleukins (IL), monocytes and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Three different subsets of monocytes, CD14brightCD16- (classical), CD14brightCD16+ (intermediate), and CD14dimCD16+ (nonclassical) have been recently identified. It has been reported that CD14brightCD16+ monocytes are increased in rheumatoid arthritis (RA). However, the role of each monocyte subset in the pathogenesis of RA is still unclear. The purpose of this study was to investigate the association of CD14brightCD16+ monocytes with RA.

Methods:  The study enrolled 35 untreated RA patients and 14 healthy volunteers. DAS28-ESR was evaluated and peripheral blood samples were obtained at baseline and following 12 weeks after methotrexate treatment. The three subsets of peripheral blood monocytes were analyzed by flow cytometry. Serum levels of cytokines were measured at baseline of the patients. CD14brightCD16- monocytes were isolated and cultured in vitro with indicated cytokines for 14 hours and assessed in CD16 induction.

Results:  The proportion of CD14brightCD16+ monocytes and serum levels of interleukin-6 (IL-6), IL-8, and IL-10 were increased in RA patients at baseline compared to healthy controls. The degree of disease activity of RA positively correlated with the proportion of CD14brightCD16+ monocytes, while proportion of CD14brightCD16- monocytes had negative correlation. When isolated CD14brightCD16- monocytes were stimulated with IL-6, IL-8, and IL-10, IL-10 was the only cytokine that remarkably induced CD16 expression on the cells. Moreover, addition of anti-IL-10 receptor blocking antibody significantly suppressed CD16 expression on CD14brightCD16- monocytes compared with that of control antibody.

Conclusion:  The proportion of CD14brightCD16+ monocytes positively correlated with RA disease activity and CD14brightCD16+ monocytes were induced from CD14brightCD16- monocytes by IL-10 but not by other cytokines upregulated in the sera from RA patients. Our results suggest that CD14brightCD16+ monocytes are possibly involved in the pathogenesis of RA and IL-10 may be a key cytokine that regulates CD14brightCD16+ monocytes.


Disclosure: M. Tsukamoto, None; N. Seta, None; K. Yoshimoto, None; K. Suzuki, None; K. Yamaoka, None; T. Takeuchi, None.

To cite this abstract in AMA style:

Tsukamoto M, Seta N, Yoshimoto K, Suzuki K, Yamaoka K, Takeuchi T. Increased Circulating CD14brightCD16+ Intermediate Monocytes Are Regulated By Interleukin-10 in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/increased-circulating-cd14brightcd16-intermediate-monocytes-are-regulated-by-interleukin-10-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-circulating-cd14brightcd16-intermediate-monocytes-are-regulated-by-interleukin-10-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology